title: [The use of the preparation Anteovin in dysfunctional uterine hemorrhages and PCOS].
abstract: The present prospective study is aimed at estimating the therapeutic effect of a biphasic oestrogen dominated contraceptive pill Anteovin in certain forms of dysfunctional uterine bleeding (DUB) and in polycystic ovary syndrome (PCOS) which is associated with dysfunctional bleeding. Two groups of women were studied--the first group (n = 34) consisted of women with DUB; the second group (n = 31) comprised PCOS. The nature and dynamics of uterine bleeding, contraceptive effectiveness and occurrence of side effects were followed up. In the second group the changes in the levels of testosterone (T), dehydroepiandrosterone sulfate (DHEA-S) and prolactin (Prl) were additionally investigated.
  
  
  RESULTS
  A significant decrease in bleeding was observed in both groups. In the second group it is in parallel with a significant decrease of T even as early as on the third month and of DHEA-S on the sixth month of treatment. No significant changes in prolactin levels were found out during the treatment.
  
  
  CONCLUSIONS
  The biphasic contraceptive pill Anteovin has a very good therapeutic effect in DUB and metrorrhagic forms of PCOS while at the same time the side effects are slightly expressed and transitory and an excellent contraception is achieved.
authors.forename: G
authors.initials: G
authors.lastname: Kolarov
authors.forename: B
authors.initials: B
authors.lastname: Nalbanski
authors.forename: M
authors.initials: M
authors.lastname: Orbetsova
authors.forename: Z
authors.initials: Z
authors.lastname: Kamenov
authors.forename: M
authors.initials: M
authors.lastname: Sirakov
authors.forename: E
authors.initials: E
authors.lastname: Filipov
mesh_terms: D000293:Adolescent; D000328:Adult; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects / Q000627:therapeutic use*; D019304:Ethinyl Estradiol-Norgestrel Combination / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006490:Hemostatics / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011446:Prospective Studies; D014592:Uterine Hemorrhage / Q000097:blood / Q000188:drug therapy* / Q000209:etiology
chemical_list: D003277:Contraceptives, Oral, Combined; D006490:Hemostatics; D019304:Ethinyl Estradiol-Norgestrel Combination